Celcuity Inc.
NASDAQCELC heads into its November earnings window with short sellers adding positions at a measured but persistent pace, even as the Street holds overwhelmingly bullish targets well above the current price. Short interest has climbed steadily through September and now accounts for nearly 25% of the free float, up roughly 20% over the past month and about 4.6% on the week alone. That is…
Snapshot as of 14 Oct 2026
CELC heads into its November earnings window with short sellers adding positions at a measured but persistent pace, even as the Street holds overwhelmingly bullish targets well above the current price. Short interest…
Celcuity heads into the final week of August with a notable split in its positioning signals — options traders are turning more bullish just as a large earnings-driven short is sitting still, and the Street's…
CELC enters its Q2 earnings release today carrying one of the most contested short books in small-cap biotech — and a month of selling that has left the stock down 17% to $86.60. Short sellers remain a dominant force.…
Celcuity enters the back half of July with a striking divergence: analysts are raising price targets while a heavy short base refuses to budge, setting up a tug-of-war that the August 14 earnings date will likely…
Celcuity enters the week after one of its sharpest single-week drops in recent memory — down 32% in five sessions and 26% on Tuesday alone, closing at $91.42. The move puts the stock more than 37% below its one-month…
CELC enters its most consequential stretch in years with a Phase 3 trial win in hand — and roughly 29% of its float still short. The news broke after market close on May 1. Celcuity announced that its VIKTORIA-1 trial…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CELC — free to start on ORTEX.
Sign up for free →Open CELC on ORTEX